Alvotech files Annual Report with the SEC
REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has filed…
Alvotech Publishes 2025 Annual Report
REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has published…
Alvotech announces European launch of first-in-market biosimilar to Simponi (golimumab) globally by partner Advanz Pharma
Introduction of AVT05 supported by NHS England tender award in the United…
Alvotech Provides Update on the Status ofU.S. Biologics License Application for AVT05
REYKJAVIK, Iceland, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a…
Advanz Pharma and Alvotech receive European approval for Mynzepli, Biosimilar to Eylea
Mynzepli® (aflibercept) is approved in all European Economic Area member countries for…
Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers
Luxembourg (July 3, 2025) – Alvotech S.A. announces that on June 25,…
Alvotechs Lenders Lower Interest on Senior Secured Term Loan Facility
REYKJAVIK, Iceland, June 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, the…
Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million
THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR…
